-

bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET. In addition to providing an overview of the business, the conference call will highlight the Company’s ongoing commercial launches of SKYSONA® and ZYNTEGLO® and the market opportunity for lovo-cel.

To access the call via telephone, please register at this link https://register.vevent.com/register/BI4fa1d86317c74333813f6827624e43ae to receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.

Contacts

Investors:

Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

Industry:

bluebird bio, Inc.

NASDAQ:BLUE
Release Versions
English

Contacts

Investors:

Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

More News From bluebird bio, Inc.

Genetix Biotherapeutics to Present Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIA™ and ZYNTEGLO™ in the U.S. has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida (December 6-9, 2025). “We are pleased to share this analysis for the first time at ASH, which demonstrates the rising acceptance and administration of our one-time gene...

bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. today announced it has rebranded as Genetix Biotherapeutics Inc., returning to its foundational roots. Genetix, now strengthened both financially and operationally, is significantly better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. The recently appointed Genetix management team, led by CEO David Meek, is...

bluebird bio Strengthens Leadership Team With New Appointments

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the appointment of Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff, further bolstering its deeply experienced management team. “I am thrilled to welcome Brian, Joanne and Adrian to bluebird’s leadership team. They each bring extensive experience in the biotech and pharmaceuti...
Back to Newsroom